Immunic, Inc. develops novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium (IMU-838), focused on multiple sclerosis. Company news commonly covers clinical and scientific presentations, patent protection for vidofludimus calcium, pipeline updates, and corporate communications tied to its late-stage development strategy.
Updates also include governance changes, board and executive appointments, Nasdaq listing compliance, capital actions such as its reverse stock split, and investor conference participation. Immunic's pipeline references additional earlier-stage programs, including IMU-856 and IMU-381, tied to neurodegenerative, chronic inflammatory, and autoimmune-related disease areas.
Immunic (Nasdaq: IMUX) closed an oversubscribed private placement on Feb 17, 2026, raising upfront gross proceeds of $200 million via issuance of 229,076,000 pre-funded warrants at $0.873 each, with warrants to purchase up to an additional $200 million.
Proceeds are intended to fund completion of the Phase 3 ENSURE trials in relapsing multiple sclerosis, initiate a Phase 3 trial in primary progressive multiple sclerosis, and support the company's transition toward a commercial organization, with cash runway expected into late 2027.
Immunic (Nasdaq: IMUX) priced a private placement for up to USD 400 million, with USD 200 million upfront to fund late‑stage programs and commercial transition. Proceeds target completion of Phase 3 ENSURE (top‑line by end‑2026), NDA submission mid‑2027, potential approval in 2028, and initiation of a Phase 3 PPMS program later in 2026. Leadership changes include Simona Skerjanec as interim chair and a CEO search for a commercial leader. The offering includes 229,076,000 pre‑funded warrants and up to 229,076,000 common warrants, expected to close about Feb 17, 2026.
Immunic (Nasdaq: IMUX) will present additional Phase 2 CALLIPER data for vidofludimus calcium at ACTRIMS Forum 2026 (Feb 5-7, San Diego). Poster data report statistically significant MRI improvements versus placebo (reduced Gd+ lesions, lower new/enlarging T2 lesion rates, T2 volume reductions, fewer SELs) and a significant decline in EBV-specific T-cell receptor matches (p=0.0004) in an 87-patient subset, suggesting antiviral activity and effects on both acute and chronic CNS inflammation.
Immunic (Nasdaq: IMUX) reported 2025 progress and near-term milestones for lead asset vidofludimus calcium and pipeline candidate IMU-856. Key achievements: completed enrollment in twin Phase 3 ENSURE trials (1,121 patients in ENSURE-1; 1,100 in ENSURE-2) with synchronized top-line data expected by end of 2026. Positive Phase 2 CALLIPER signals in progressive MS showed reductions in 24-week confirmed disability worsening and >2x probability of 24-week confirmed disability improvement. Long-term OLE EMPhASIS data showed 92.3% free of 12wCDW and 92.7% free of 24wCDW at week 144. USPTO notice allows patent protection into 2041. Company raised capital via $5.1M direct and $65M public offerings.
Immunic (Nasdaq: IMUX) announced that CEO Daniel Vitt, Ph.D. will participate in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference on Thursday, December 4, 2025 at 9:35 am ET in Coral Gables, FL.
A webcast will be available in the Events and Presentations section of Immunic's investor website at https://ir.imux.com/events-and-presentations. Dr. Vitt and President/COO Jason Tardio will also hold one-on-one investor meetings during the conference; meeting requests can be made through Evercore ISI representatives or by contacting Jessica Breu at jessica.breu@imux.com.
Immunic (Nasdaq: IMUX) reported Q3 2025 results and clinical updates on November 13, 2025. Key clinical highlights include statistically significant 24-week confirmed disability improvement (24wCDI) from the phase 2 CALLIPER trial in progressive MS and supportive long-term EMPhASIS OLE data showing ~952 cumulative treatment years and an annualized discontinuation rate of ~6.4% up to 5.5 years.
The company received a U.S. patent allowance covering vidofludimus calcium dose strengths, expected to provide protection into 2041. Twin phase 3 ENSURE trials top-line data in relapsing MS are expected by year-end 2026.
Financials: Q3 net loss was ~$25.6M (Q3) and ~$77.9M (nine months); cash and equivalents were $35.1M with insufficient liquidity to fund operations for 12 months without additional capital.
Immunic (Nasdaq: IMUX) will participate in industry and investor conferences in November 2025. Company executives will attend BIO-Europe in Vienna on Nov 3–5, 2025 for partnering activities, with Daniel Vitt, Ph.D., Hella Kohlhof, Ph.D., and Jessica Breu representing the company.
Immunic executives will also host one-on-one meetings in London on Nov 19–20, 2025 in connection with the Jefferies Global Healthcare Conference—London; Daniel Vitt and Jason Tardio will attend. To schedule meetings, contact Jessica Breu via jessica.breu@imux.com or use the BIO-Europe partneringONE portal.
Immunic (NASDAQ: IMUX), a biotechnology company focused on inflammatory and autoimmune diseases, has announced its participation in several key scientific and investor conferences in October 2025. The company will present data on two key products: IMU-856, a SIRT6 modulator for celiac disease, at the United European Gastroenterology Week (UEGW), and vidofludimus calcium (IMU-838), a Nurr1 activator, at the International Society of Neuroimmunology Congress.
Management will also participate in investor-focused events, including Roth's 4th Annual Healthcare Opportunities Conference and a virtual fireside chat with H.C. Wainwright, providing opportunities for investor engagement and company updates.
Immunic (NASDAQ:IMUX) presented key data for vidofludimus calcium in multiple sclerosis at the 41st ECTRIMS Congress. The phase 2 CALLIPER trial demonstrated statistically significant results in progressive multiple sclerosis, showing over two-fold probability of 24-week confirmed disability improvement versus placebo.
The drug reduced the risk of 24-week confirmed disability worsening by 23.8% versus placebo in the overall population and by 33.7% in patients without gadolinium-enhancing lesions. Long-term data from the Phase 2 EMPhASIS trial in relapsing-remitting MS showed 92.3% of patients remained free of 12-week confirmed disability worsening at week 144, with favorable safety profiles.
Immunic (NASDAQ:IMUX) has received a Notice of Allowance from the USPTO for a patent application covering dose strengths of its lead asset vidofludimus calcium (IMU-838) for treating progressive multiple sclerosis (PMS). The patent specifically covers daily doses of 10-45mg for treating PMS, including primary and secondary progressive forms.
The patent provides protection until 2041 and follows positive phase 2 CALLIPER trial results where vidofludimus calcium demonstrated neuroprotective potential by delaying time to 24-week confirmed disability worsening (24wCDW). The drug also showed reductions in thalamic brain volume loss and volume of new/enlarging T2 lesions.
This is the fifth U.S. patent for vidofludimus calcium in multiple sclerosis, part of a multi-layered intellectual property strategy that includes patents for composition-of-matter, treatment methods, and dosing regimens.